Drug Information

Drug (ID: DG01805) and It's Reported Resistant Information

• Name: Homocysteine
• Synonyms: L-Homocysteine; homocysteine; 6027-13-0; (2S)-2-amino-4-sulfanylbutanoic acid; (s)-2-amino-4-mercaptobutanoic acid; UNII-0LVT1QZ0BA; 2-AMINO-4-MERCAPTO-BUTYRIC ACID; CHEBI:17588; L-2-Amino-4-mercaptobutyric acid; 0LVT1QZ0BA; CHEMBL469662; Hcy; MFCD00151320; homo-cys; H-Hcys-OH; Butyric acid, 2-amino-4-mercapto-; HCS; Homocysteine (VAN); 454-28-4; 2-amino-4-sulfanylbutanoate; EINECS 227-891-0; NSC 43117; NSC 118376; 2-Amino-4-mercaptobutyric acid (VAN); Butanoic acid, 2-amino-4-mercapto- (VAN); Butanoic acid, 2-amino-4-mercapto-, (S)-; Epitope ID:143650; SCHEMBL35837; 2-amino-4-mercapto-Butanoate; GTPL5198; DTXSID3041039; 2-amino-4-mercapto-DL-Butyrate; 2-amino-4-mercapto-Butanoic acid; ZINC895077; (S)-2-amino-4-mercapto-Butanoate; L-2-amino-4-mercapto-Butyric acid; (S)-2-Amino-4-mercaptobutyric acid; 2-amino-4-mercapto-DL-Butyric acid; BDBM50242405; DL-2-amino-4-mercapto-Butyric acid; L-Homocysteine, >=98.0% (NT); AKOS006272166; (S)-2-amino-4-mercapto-Butanoic acid; CS-W011063; DB04422; FS-6405; HY-W010347; Butyric acid, 2-amino-4-mercapto- (8CI); C00155; H-2800; I11579; Butyric acid, 2-amino-4-mercapto-, L- (8CI); A832662; Q26992833; UNII-S7IJP4A89K component FFFHZYDWPBMWHY-VKHMYHEASA-N
• Indication:
  In total 1 Indication(s)
  Discovery agent [ICD-11: N.A.]; Investigative; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Cardiovascular injury [ICD-11: BE2Z]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 3
• IsoSMILES: C(CS)[C@@H](C(=O)O)N
• InChI: InChI=1S/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m0/s1
• InChIKey: FFFHZYDWPBMWHY-VKHMYHEASA-N
• PubChem CID: 91552
• ChEBI ID: CHEBI:17588
• TTD Drug ID: D0U6ZD
• DrugBank ID: DB04422

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-11: Circulatory system diseases

Cardiovascular injury [ICD-11: BE2Z]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Growth arrest specific 5 (GAS5) [1]

• Molecule Alteration: Down-regulation; Interaction
• Resistant Disease: Cardiac microvascular endothelial cells injury [ICD-11: BE2Z.Y]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: ECs; N.A.; Drosophila melanogaster (Fruit fly); CVCL_Z893
• In Vitro Model: CMECs; N.A.; .; N.A.
• Experiment for Molecule Alteration: Overexpression assay
• Experiment for Drug Resistance: MTT assay; EdU assay; TUNEL staining assay; Caspase-3 activity detection; Dual luciferase reporter gene assay
• Mechanism Description: Long-chain noncoding RNA GAS5 mediates oxidative stress in cardiac microvascular endothelial cells injury.

References

• Ref 1: lncRNA GAS5 restrains CCl(4)-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathwayAm J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G539-G550. doi: 10.1152/ajpgi.00249.2018. Epub 2019 Feb 8.